- Home
- PBH vs VKTX Comparison
PBH vs VKTX Comparison
Compare PBH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBH | VKTX |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PBH | VKTX |
|---|---|---|
| Price | $63.46 | $35.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $80.75 | ★ $88.00 |
| AVG Volume (30 Days) | 358.7K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $975,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.15 | N/A |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $57.25 | $18.92 |
| 52 Week High | $88.55 | $43.15 |
Technical Indicators
Market Signals| Indicator | PBH | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 58.25 |
| Support Level | $62.84 | $33.65 |
| Resistance Level | $68.51 | $35.66 |
| Average True Range (ATR) | 1.72 | 1.73 |
| MACD | -0.73 | 0.37 |
| Stochastic Oscillator | 2.88 | 76.00 |
Price Performance
Historical ComparisonAbout PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.